Get the Stockscreener App
0.886
4.19%
-0.0387
After Hours:
.96
0.074
+8.35%
Filana Therapeutics Inc stock is traded at $0.886, with a volume of 766.49K.
It is down -4.19% in the last 24 hours and down -4.63% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$0.9247
Open:
$0.9299
24h Volume:
766.49K
Relative Volume:
0.42
Market Cap:
$42.80M
Revenue:
-
Net Income/Loss:
$-77.90M
P/E Ratio:
-0.5494
EPS:
-1.6127
Net Cash Flow:
$-30.38M
1W Performance:
+1.83%
1M Performance:
-4.63%
6M Performance:
-45.31%
1Y Performance:
+0.00%
1-Day Range:
$0.8641
$0.9467
1-Week Range:
$0.72
$0.9467
52-Week Range:
$0.6701
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
0.886 | 36.14M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
522.81 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
758.27 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
192.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.91 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
Filana Therapeutics Inc. (FLNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top Movers: US Stock Gainers and Losers Today - ChartMill
Top US Stock Movers: Today's Session Gainers and Losers - ChartMill
Which stocks are experiencing notable movement on Tuesday? - ChartMill
Which stocks are most active on Tuesday? - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Filana Therapeutics Stock Trading Higher Today?Filana Therapeutics (NASDAQ:FLNA) - Benzinga
Gapping stocks in Tuesday's session - ChartMill
FDA Lifts Clinical Hold on Filana Therapeutics’ Simufilam IND - Minichart
Filana Therapeutics advances simufilam in TSC epilepsy trial - TipRanks
Filana TherapeuticsFDA Lifts Clinical Hold On Filana's Simufilam For TSC-Related Epilepsy - TradingView
FLNA Stock Edges Higher: Filana Therapeutics Ticks Up 1.79% to $0.74Put Spread Alert - siam.in
FDA clears Filana (NASDAQ: FLNA) to test simufilam in hard-to-treat seizures - Stock Titan
A rare epilepsy trial can now move ahead after FDA lifts its hold on simufilam. - Stock Titan
Filana Therapeutics, Inc.(NasdaqCM: FLNA) dropped from S&P Global BMI Index - marketscreener.com
Filana Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (FLNA) - Traders Union
FLNA Should I Buy - Intellectia AI
Filana Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks
Filana Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Filana Therapeutics, Inc. Stock Price Today | FLNA Live Chart & News - Traders Union
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Beats Consensus by 20%Earnings Risk Report - dars.gov.et
September 2026 Stock Gainers on News, MTD: 100 Moves - Stock Titan
Filana (FLNA) Latest Quarter: EPS Clears the Reported Estimate in the Latest Reading; Post-Report: Shares Close 3.23% Lower in Latest TradingEarnings Miss Streak - vinanet.vn
Filana (FLNA) Earnings Snapshot: The EPS Result Is Above Expectation in Latest Trading; After Results: The Market Price Declines 3.72% for the Current SessionMargin Compression Risk - vinanet.vn
Filana Therapeutics, Inc. (NASDAQ: FLNA) Share Price, FLNA Stock News, FLNA Share Price & Updates - Kalkine
Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071 - marketscreener.com
Cassava Sciences Securities Litigation Ruling: Court Denies Ugarte Dismissal Motions Without Prejudice While Awaiting Fifth Circuit Ruling - TipRanks
Law firm investigates Filana Therapeutics officers for possible shareholder rights breaches - Pluang
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
FLNA Q3 2025 Earnings: Narrower Loss Beats Estimates by 20.12% as Shares Dip 2.58%Earnings Manipulation Risk - vinanet.vn
FLNA Q3 2025 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseOne-Time Gain Impact - dars.gov.et
Filana Therapeutics (FLNA) Climbs 3.75% as Micro-Cap Biotech Approaches Key Resistance at $1.04Volatility Smile - dars.gov.et
Filana Therapeutics (FLNA) Slides 3.3% to $1.00 as Small-Cap Biotech Approaches Key SupportSector ETF Flow - careplusvn.com
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView
FLNA Q3 2025 Earnings: Narrower-than-Expected Loss Lifts Shares 5.21%Buyback Announcement Report - dars.gov.et
Maxim Group Maintains Filana Therapeutics(FLNA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update - GlobeNewswire
Filana Therapeutics Faces Pressure as Shares Slide 4.43%Support at $0.85 in FocusIV Spike - vinanet.vn
Filana Therapeutics, Inc. Revenue Breakdown – NASDAQ:FLNA - TradingView
Filana Therapeutics (FLNA) AGM 2026 Summary - Quartr
Filana Therapeutics (FLNA) Q4 2025 earnings summary - Quartr
Filana Therapeutics (FLNA) Slides 5% as Bearish Momentum Builds; Key Support at $1.04 in FocusATR Stop - dars.gov.et
MSN Money - MSN
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Despite Stock SlideEPS Surprise History - dars.gov.et
Filana Therapeutics (FLNA) Surges 4.8% as Biotech Momentum BuildsUpthrust Pattern - dars.gov.et
FLNAFilana Therapeutics Inc Short Interest - Finviz
Price to sales forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Price to book forward of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (NASDAQ:FLNA) - TradingView
Filana Therapeutics, Inc. Actuals & Estimates (TRADEGATE:PX91) - TradingView
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Filana Therapeutics Inc Stock (FLNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
1.29%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):